Sedation and Neuromediators Concentration

• Status: Completed
• Trial end date: 2021-04-15
• Target enrollment: 0
• Participant gender: All

Summary

Propofol (Propofol Kabi, Registration number from the State Register of Medicines - 000875) is a widely used intravenous anesthetic. It is well known about different effects of propofol infusion, including euphoria, psycholalia, disinhibition, talkativeness, satisfaction etc. However, the basic mechanisms of such effects remain unknown. We suppose that propofol sedation with various levels of sedation (from light to deep) leads to neuromediators changes. We examine dopamine, noradrenaline, acetylcholine, GABA and serotonin in peripheral venous blood before, during and after propofol sedation. Therefore, we suppose drugs for sedation, in particular, propofol will affect neuromediators concentration.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: I.M. Sechenov First Moscow State Medical University
• Treatments: Propofol

Criteria

Inclusion Criteria:

• Written informed consent

• Age ≥ 18 years

• Elective trauma surgery (arthroscopy, reconstructive foot surgery, osteosynthesis of intra-and periarticular fractures of the proxymal humerus) under regional anesthesia (spinal anesthesia or brachial plexus block) with propofol sedation

• Montreal cognitive assessment test ≥ 26

• Patients with American Society of Anesthesiologists (ASA) I-II

Non-inclusion criteria:

• Not written informed consent

• Age˂18 years

• Allergy to sedation drugs

• Pregnancy

• Epilepsy anamnesis

• II-III degree atrioventricular block

• Montreal cognitive assessment test ˂ 26

• Patients with American Society of Anesthesiologists (ASA) ˃ II

• The presence of psychiatric disorders

• Сancer patients with a life expectancy of less than two years

Exclusion Criteria:

• Patient refuse from further participation

• Transition from sedation to general anesthesia

• Allergy on anesthesia drugs during perioperative period